EXCHANGE AGREEMENTExchange Agreement • September 12th, 2017 • Inspyr Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, pursuant to that certain Securities Purchase Agreement, by and among the Company and the purchasers signatory thereto, dated as of December 23, 2015 (the “2015 Purchase Agreement”), the Company issued to the Holders shares of the Company’s Series A 0% Convertible Preferred Stock (the “Series A Preferred Stock”) convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), of which an aggregate of 1,614.8125 are being exchanged hereunder;
